With the recent announcement confirming the increased number of PML cases, other information has become available as well. Of the 24 cases, two-thirds have been in Europe and one-third in…
Read More
The diagnosis of “secondary progressive MS” has long been thought to mark a shift in the course of the disease from a primarily inflammatory process to a neurodegenerative one. Although the majority of people with…
Fingolimod is an oral agent that is now being researched in three Phase III trials. This is the first of a new class of potential MS medications known as “S1P…
Laquinimod Laquinimod is an investigational, oral, once-daily therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS). The therapy (licensed to Teva Neuroscience) received Fast Track designation—meaning the therapy demonstrated the…
To view the video presentations, scroll down and click on the images below. The presentation’s title and presenter name will appear once you click on the image you want to…
These days the term “self-care” is thrown around casually and frequently. It’s become trendy, a bit of a buzz word, and it’s often misunderstood. The commercial wellness industry would have…